New drug combo targets rare cancers in early trial

NCT ID NCT00336063

First seen Feb 28, 2026 · Last updated Jun 12, 2026 · Updated 15 times

Summary

This early-phase trial tested the safety and best dose of two drugs, vorinostat and azacitidine, given together to adults with advanced nasopharyngeal cancer or a rare nasal lymphoma that had come back or spread. The goal was to find a dose that limits side effects while potentially stopping cancer growth. The study enrolled 18 people and is no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL KERATINIZING SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chinese University of Hong Kong-Prince of Wales Hospital

    Shatin, Hong Kong

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • National Cancer Center Hospital

    Tokyo, 104 0045, Japan

  • National Cancer Centre Singapore

    Singapore, 168583, Singapore

  • National University Hospital Singapore

    Singapore, 119074, Singapore

Conditions

Explore the condition pages connected to this study.